BioStock: Full speed ahead for Elicera in 2024

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved phase I/IIa study with lead CAR T candidate ELC-301, made possible by a major financing round coming later this month. Speaking to Elicera’s CEO Jamal El-Mosleh, it’s clear that the company is ready for a busy 2024, where now two pipeline candidates are in the clinic.

Read the full interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2024/02/full-speed-ahead-for-elicera-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/